JiÅÃ[™] WidimskÃ¹⁄₂ Jr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1553520/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
3	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	3.6	310
4	Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. European Heart Journal, 2014, 35, 3122-3133.	2.2	249
5	Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. Journal of Human Hypertension, 2003, 17, 349-352.	2.2	213
6	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. New England Journal of Medicine, 2016, 374, 1521-1532.	27.0	204
7	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. Hypertension, 2015, 65, 407-413.	2.7	178
8	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
9	Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension, 2017, 69, 1113-1120.	2.7	150
10	Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes. Hypertension, 2003, 41, 1063-1071.	2.7	142
11	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of Hypertension, 2006, 24, 1405-1412.	0.5	139
12	High Incidence of Cardiovascular Complications in Pheochromocytoma. Hormone and Metabolic Research, 2012, 44, 379-384.	1.5	138
13	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. Journal of Hypertension, 2013, 31, 2455-2461.	0.5	136
14	Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension, 2017, 70, 1042-1048.	2.7	132
15	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	3.9	117
16	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. Endocrine Practice, 2016, 22, 302-314.	2.1	110
17	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension, 2019, 74, 800-808.	2.7	97
18	Increased Arterial Wall Stiffness in Primary Aldosteronism in Comparison With Essential Hypertension. American Journal of Hypertension, 2006, 19, 909-914.	2.0	96

#	Article	IF	CITATIONS
19	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	2.7	94
20	Comparison of the Insulin Action Parameters from Hyperinsulinemic Clamps with Homeostasis Model Assessment and QUICKI Indexes in Subjects with Different Endocrine Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 135-141.	3.6	93
21	Adrenalectomy Improves Arterial Stiffness in Primary Aldosteronism. American Journal of Hypertension, 2008, 21, 1086-1092.	2.0	89
22	Increased intima–media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. Journal of Hypertension, 2007, 25, 1451-1457.	0.5	85
23	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.5	74
24	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. Hypertension, 2016, 67, 397-403.	2.7	73
25	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	1.5	65
26	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2042-2052.	3.6	65
27	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	2.7	61
28	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocrine-Related Cancer, 2008, 15, 311-323.	3.1	60
29	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. Journal of Human Hypertension, 2010, 24, 625-630.	2.2	57
30	Diurnal blood pressure variationin pheochromocytoma, primary aldosteronism and Cushing's syndrome. Journal of Human Hypertension, 2004, 18, 107-111.	2.2	49
31	Changes in Energy Metabolism in Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1651-1658.	3.6	49
32	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. Journal of Hypertension, 2005, 23, 2033-2039.	0.5	45
33	Metastatic pheochromocytoma: Does the size and age matter?. European Journal of Clinical Investigation, 2011, 41, 1121-1128.	3.4	42
34	Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertension Research, 2011, 34, 296-300.	2.7	42
35	Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 586.	3.7	42
36	Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity, Journal of Human Hypertension, 2002, 16, 41-45	2.2	39

#	Article	IF	CITATIONS
37	Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. NeuroImmunoModulation, 2007, 14, 57-64.	1.8	38
38	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 2020, 41, 2356-2362.	2.2	38
39	Long-term effect of specific treatment of primary aldosteronism on carotid intima–media thickness. Journal of Hypertension, 2015, 33, 874-882.	0.5	35
40	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertension Research, 2010, 33, 454-459.	2.7	34
41	30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 – 2016/17. PLoS ONE, 2020, 15, e0232845.	2.5	34
42	Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. Kidney and Blood Pressure Research, 2012, 35, 529-533.	2.0	30
43	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1109-1117.	1.7	29
44	Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5170-5180.	3.6	28
45	Determination of doxazosin and verapamil in human serum by fast LC–MS/MS: Application to document non-compliance of patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3167-3173.	2.3	26
46	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. Journal of Hypertension, 2017, 35, 1093-1099.	0.5	25
47	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	3.9	25
48	Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?. Journal of Human Hypertension, 2014, 28, 684-688.	2.2	23
49	Recent Advances in the Diagnosis and Treatment of Pheochromocytoma. Kidney and Blood Pressure Research, 2006, 29, 321-326.	2.0	20
50	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. Journal of Hypertension, 2018, 36, 221-229.	0.5	20
51	Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. Journal of Human Hypertension, 2016, 30, 35-39.	2.2	19
52	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
53	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	3.6	18
54	Primary Aldosteronism and Pregnancy. Kidney and Blood Pressure Research, 2020, 45, 275-285.	2.0	16

#	Article	IF	CITATIONS
55	Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. Journal of Human Hypertension, 2009, 23, 350-358.	2.2	15
56	Comparison of three office blood pressure measurement techniques and their effect on hypertension prevalence in the general population. Journal of Hypertension, 2020, 38, 656-662.	0.5	15
57	Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration. Blood Pressure, 2006, 15, 302-307.	1.5	14
58	Characteristics of Blood Pressure in Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 86-93.	3.8	14
59	Discrepant Results of Adrenal Venous Sampling in Seven Patients with Primary Aldosteronism. Kidney and Blood Pressure Research, 2012, 35, 205-210.	2.0	14
60	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2422.	3.6	14
61	Catecholamines Induce Left Ventricular Subclinical Systolic Dysfunction: A Speckle-Tracking Echocardiography Study. Cancers, 2019, 11, 318.	3.7	13
62	Pheochromocytoma With Adrenergic Biochemical Phenotype Shows Decreased GLP-1 Secretion and Impaired Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1878-1887.	3.6	13
63	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	2.7	13
64	Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Blood Pressure, 2008, 17, 170-177.	1.5	12
65	Expert consensus statement of the Czech Society of Cardiology and the Czech Society of Hypertension on catheter-based sympathetic renal denervation procedures (RDN) in the Czech Republic. Cor Et Vasa, 2012, 54, e108-e112.	0.1	10
66	Abolished nocturnal blood pressure fall in a boy with glucocorticoid-remediable aldosteronism. Journal of Human Hypertension, 1999, 13, 823-828.	2.2	9
67	Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. Cor Et Vasa, 2014, 56, e235-e239.	0.1	9
68	Plasma endothelin-1,2 levels in mild and severe hypertension. Journal of Hypertension, 1991, 9, S196.	0.5	9
69	Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. Current Medical Research and Opinion, 2006, 22, 1287-1294.	1.9	8
70	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 426-434.	1.7	8
71	Development of a fast LC–MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS. Journal of Mass Spectrometry, 2010, 45, 1179-1185.	1.6	7
72	Distinct plasma atrial natriuretic factor, renin and aldosterone responses to prolonged high-salt intake in hypertensive and normotensive rats. Journal of Hypertension, 1991, 9, 241-242.	0.5	6

#	Article	IF	CITATIONS
73	Paraganglioma in a 13-year-old girl: a novel SDHB gene mutation in the family?. Cancer Genetics and Cytogenetics, 2010, 197, 189-192.	1.0	6
74	Should All Patients with Resistant Hypertension Receive Spironolactone?. Current Hypertension Reports, 2016, 18, 81.	3.5	6
75	Adrenal Venous Sampling Could Be Omitted before Surgery in Patients with Conn's Adenoma Confirmed by Computed Tomography and Higher Normal Aldosterone Concentration after Saline Infusion Test. Diagnostics, 2022, 12, 1718.	2.6	6
76	Atrial Natriuretic Peptide Concentration and Natriuretic Hormone Activity in Plasma of Patients with Chronic Renal Failure. Hormone and Metabolic Research, 1988, 20, 709-712.	1.5	5
77	Technical and safety aspects of renal denervation. Cor Et Vasa, 2014, 56, e228-e234.	0.1	5
78	An update of the expert consensus statement of the Czech Hypertension Society on renal denervation in resistant hypertension. Cor Et Vasa, 2015, 57, e187-e189.	0.1	5
79	Effect of adrenalectomy on remission of subclinical left ventricular dysfunction in patients with pheochromocytoma: a speckle-tracking echocardiography study. Endocrine Connections, 2021, 10, 1538-1549.	1.9	5
80	Plasma Concentration and Urinary Excretion of Arginine-Vasopressin in Primary Aldosteronism during the Fluid Deprivation Tests. Experimental and Clinical Endocrinology and Diabetes, 1983, 82, 347-355.	1.2	4
81	Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?. Journal of Clinical Hypertension, 2020, 22, 897-905.	2.0	4
82	Primary aldosteronism in a general population sample. The Czech post-MONICA study. Blood Pressure, 2020, 29, 191-198.	1.5	4
83	The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension — the VICTORY trial. Kardiologia Polska, 2017, 75, 55-64.	0.6	4
84	Arterial hypertension and atrial fibrillation: selecting antihypertensive therapy. Cor Et Vasa, 2012, 54, e248-e252.	0.1	3
85	Summary of 2013 ESH/ESC Guidelines for the management of arterial hypertension. Prepared by the Czech Society of Hypertension/Czech Society of Cardiology. Cor Et Vasa, 2014, 56, e494-e518.	0.1	3
86	The role of arterial hypertension in the primary prevention of stroke. Cor Et Vasa, 2016, 58, e279-e286.	0.1	3
87	Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer. European Journal of Internal Medicine, 2020, 79, 63-69.	2.2	3
88	Gene Profile of Adipose Tissue of Patients with Pheochromocytoma/Paraganglioma. Biomedicines, 2022, 10, 586.	3.2	3
89	Effect of prolonged high salt intake on atrial natriuretic factor's kinetics in rats. Peptides, 1990, 11, 501-506.	2.4	2
90	Increased carotid intima–media thickness in hypertensive patients with a high aldosterone/plasma renin activity ratio and elevated aldosterone plasma concentration. Journal of Hypertension, 2008, 26, 1500-1501.	0.5	2

#	Article	IF	CITATIONS
91	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. Cancers, 2019, 11, 485.	3.7	2
92	Postoperative adrenal insufficiency in Conn's syndrome—does it occur frequently?. Journal of Human Hypertension, 2021, , .	2.2	2
93	Biochemical Testing After Pheochromocytoma Removal: How Early?. Hormone and Metabolic Research, 2015, 47, 633-636.	1.5	1
94	How to assess non-compliance with the pharmacotherapy in severe resistant hypertension?. Cor Et Vasa, 2011, 53, 429-432.	0.1	1
95	Adherence and blood pressure control in patients with primary aldosteronism. Blood Pressure, 2022, 31, 58-63.	1.5	1
96	Dissociation between right atrial pressure and plasma atrial natriuretic factor following prolonged high salt intake. Canadian Journal of Physiology and Pharmacology, 1990, 68, 408-412.	1.4	0
97	The effect of perindopril on arterial stiffness and endothelial function in patients with stable coronary artery disease. Atherosclerosis, 1999, 144, 54-55.	0.8	0
98	We-P11:195 Comparison of carotid intima-media thickness in patients with primary and secondary hypertension. Atherosclerosis Supplements, 2006, 7, 389.	1.2	0
99	INCREASED CAROTID INTIMA MEDIA THICKNESS IN PATIENTS WITH PHEOCHROMOCYTOMA IN COMPARISON TO ESSENTIAL HYPERTENSION. Atherosclerosis Supplements, 2008, 9, 158.	1.2	0
100	Laparoscopic adrenalectomy: institutional Czech experience after almost 300 operations. European Surgery - Acta Chirurgica Austriaca, 2016, 48, 121-124.	0.7	0
101	(Prediction of long-term renal denervation efficacy). Cor Et Vasa, 2019, 61, e378-e384.	0.1	0
102	Otto Klein from Prague University Hospital performed the world first diagnostic cardiac catheterization in 11 Czech patients in 1929. European Heart Journal, 2020, 41, 1323-1325.	2.2	0
103	Pheochromocytoma - tumor interesting also for cardiologists. Cor Et Vasa, 2011, 53, 454-460.	0.1	0
104	The revival of catheter-based renal denervation?. Intervencni A Akutni Kardiologie, 2018, 17, 159-163.	0.0	0
105	Reply. Journal of Hypertension, 2020, 38, 1860-1861.	0.5	0